R&D News | pharmaphorum

News

Gilead finds survival boost with remdesivir with unorthodox ...

Gilead says an analysis of clinical trial and retrospective real-world data suggest remdesivir can improve survival in severe COVID-19 infections, but adds controlled studies a

News

Pharma companies create $1bn fund to save antibiotic researc...

More than 20 pharma companies including GlaxoSmithKline, Novartis and Pfizer have joined forces to create a $1 billion fund to save the pipeline of antibiotics drugs, after several biotechs

News

Kymera Therapeutics begins potential $2bn R&D deal with Sano...

US biotech Kymera Therapeutics has begun a strategic collaboration with Sanofi to develop and market several drugs tackling immune-inflammatory disease, which could be worth up to $2 billio

News

Gilead starts trials of inhaled remdesivir for earlier-stage...

The first healthy volunteers have started to receive doses of Gilead’s inhaled formulation of remdesivir, which it hopes could become an option for earlier-stage COVID-19 outsi

News

Regeneron begins late-stage trial testing COVID-19 antibody ...

Regeneron has begun a late-stage clinical trial testing its double “antibody cocktail” as a preventive treatment for COVID-19.

News

UK trial begins testing second-wave COVID-19 drug from US bi...

The AGILE programme, which is researching a second wave of COVID-19 therapies in the UK, has begun testing its first potential drug that researchers hope could alter the course of the pande

Gilead finds survival boost with remdesivir with unorthodox ...

Pharma companies create $1bn fund to save antibiotic researc...

Kymera Therapeutics begins potential $2bn R&D deal with Sano...

Gilead starts trials of inhaled remdesivir for earlier-stage...

Regeneron begins late-stage trial testing COVID-19 antibody ...

UK trial begins testing second-wave COVID-19 drug from US bi...

Hengrui gets world-first okay for platelet drug hetrombopag

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks